Go offline with the Player FM app!
Ipsen advances liver disease treatment
Manage episode 386941052 series 3361449
Jennifer Schranz is senior vice president and global head of rare diseases in the R&D division at Ipsen.
On the podcast this week, she discusses a breakthrough treatment for primary biliary cholerangitis and cholestatic liver disease.
00:56-00:49: Background information
01:44-03:21: What are primary biliary cholerangitis (PBC) and cholestatic liver disease?
03:21-03:50: How rare is PBC?
03:50-04:45: How easy is PBC diagnosis?
04:45-05:45: What are the current treatments for the condition?
05:45-07:22: What are the challenges to innovation?
07:22-08:27: What is elafibranor?
08:27-08:37: How is it administered?
08:37-09:18: Is elafibranor taken for life?
09:18-11:08: What is the ELATIVE trial, and what were the results you presented at the AASLD Liver Meeting?
11:08-13:09: What was the reaction at the meeting?
13:09-13:55: A patient-centric approach
13:55-14:44: Is a cure for PBC a possibility?
14:44-17:20: How important are acquisitions to Ipsen’s pipeline?
17:20-18:33: Working on multiple diseases
18:33-19:58: How much impact can you have on liver diseases?
19:58-21:04: What are the next steps for elafibranor?
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
Chapters
1. Ipsen advances liver disease treatment (00:00:00)
2. Background information (00:00:56)
3. What are primary biliary cholerangitis (PBC) and cholestatic liver disease? (00:01:44)
4. How rare is PBC? (00:03:21)
5. How easy is PBC diagnosis? (00:03:50)
6. What are the current treatments for the condition? (00:04:45)
7. What are the challenges to innovation? (00:05:45)
8. What is elafibranor? (00:07:22)
9. Is elafibranor taken for life? (00:08:27)
10. How is elafibranor administered? (00:08:27)
11. What is the ELATIVE trial, and what were the results you presented at the AASLD Liver Meeting? (00:09:18)
12. What was the reaction at the meeting? (00:11:08)
13. A patient-centric approach (00:13:09)
14. Is a cure for PBC a possibility? (00:13:55)
15. How important are acquisitions to Ipsen’s pipeline? (00:14:44)
16. Working on multiple diseases (00:17:20)
17. How much impact can you have on liver diseases? (00:18:33)
18. What are the next steps for elafibranor? (00:19:58)
112 episodes
Manage episode 386941052 series 3361449
Jennifer Schranz is senior vice president and global head of rare diseases in the R&D division at Ipsen.
On the podcast this week, she discusses a breakthrough treatment for primary biliary cholerangitis and cholestatic liver disease.
00:56-00:49: Background information
01:44-03:21: What are primary biliary cholerangitis (PBC) and cholestatic liver disease?
03:21-03:50: How rare is PBC?
03:50-04:45: How easy is PBC diagnosis?
04:45-05:45: What are the current treatments for the condition?
05:45-07:22: What are the challenges to innovation?
07:22-08:27: What is elafibranor?
08:27-08:37: How is it administered?
08:37-09:18: Is elafibranor taken for life?
09:18-11:08: What is the ELATIVE trial, and what were the results you presented at the AASLD Liver Meeting?
11:08-13:09: What was the reaction at the meeting?
13:09-13:55: A patient-centric approach
13:55-14:44: Is a cure for PBC a possibility?
14:44-17:20: How important are acquisitions to Ipsen’s pipeline?
17:20-18:33: Working on multiple diseases
18:33-19:58: How much impact can you have on liver diseases?
19:58-21:04: What are the next steps for elafibranor?
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
Chapters
1. Ipsen advances liver disease treatment (00:00:00)
2. Background information (00:00:56)
3. What are primary biliary cholerangitis (PBC) and cholestatic liver disease? (00:01:44)
4. How rare is PBC? (00:03:21)
5. How easy is PBC diagnosis? (00:03:50)
6. What are the current treatments for the condition? (00:04:45)
7. What are the challenges to innovation? (00:05:45)
8. What is elafibranor? (00:07:22)
9. Is elafibranor taken for life? (00:08:27)
10. How is elafibranor administered? (00:08:27)
11. What is the ELATIVE trial, and what were the results you presented at the AASLD Liver Meeting? (00:09:18)
12. What was the reaction at the meeting? (00:11:08)
13. A patient-centric approach (00:13:09)
14. Is a cure for PBC a possibility? (00:13:55)
15. How important are acquisitions to Ipsen’s pipeline? (00:14:44)
16. Working on multiple diseases (00:17:20)
17. How much impact can you have on liver diseases? (00:18:33)
18. What are the next steps for elafibranor? (00:19:58)
112 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.